Overview Technical Risk & rank Results Accounts Filings Guidance & governance
Guidance tracker
What ANTHEM guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 06 Nov 2026 | Anthem Biosciences filed the transcript of its Q2 and H1 FY27 earnings conference call held on November 04, 2026, after announcing results for the quarter and half year ended September 30, 2026. Management (CEO Ajay Bhardwaj) said Q2 FY27 consolidated revenue from operations was INR594 crores, with CRDMO revenue of... NSE copy | No results filed since | ||
| 27 Jul 2026 | Anthem Biosciences filed the transcript of its Q1 FY27 earnings conference call held on July 22, 2026, after announcing results for the quarter ended June 30, 2026. Management (MD and CEO Ajay Bhardwaj) reported consolidated revenue from operations of Rs. 418 crores, with CRDMO contributing Rs. 341 crores (81.5%)... NSE copy | +21.9 % | +8.0 % | +4.0 % |
| 21 Jul 2026 | Anthem Biosciences filed a revised earnings call presentation for the quarter ended June 30, 2026, superseding the presentation filed earlier on July 21, 2026. Q1FY27 consolidated revenue from operations was ₹4,182 Mn (down 22.6% YoY from ₹5,402 Mn); CRDMO revenue ₹3,408 Mn and Specialty Ingredients ₹774 Mn. Q1FY27... NSE copy | +21.9 % | +8.0 % | +4.0 % |
| 21 Jul 2026 | Anthem Biosciences filed its earnings call presentation on unaudited consolidated results for the quarter ended June 30, 2026 (Q1FY27), ahead of the earnings call on July 22, 2026. Q1FY27 revenue from operations was ₹4,182 Mn, down 22.6% YoY from ₹5,402 Mn; PAT was ₹1,199 Mn, down 11.7% YoY from ₹1,358 Mn; EBITDA... NSE copy | +21.9 % | +8.0 % | +4.0 % |
| 22 May 2026 | Anthem Biosciences filed the transcript of its Q4 & FY26 earnings conference call held May 20, 2026, after announcing audited results for the quarter and year ended March 31, 2026. FY26 consolidated revenue from operations was Rs. 2,124 crores (CRDMO Rs. 1,773 crores, up 18%; specialty ingredients Rs. 352 crores);... NSE copy | -11.7 % | -22.6 % | -1.6 % |
| 19 May 2026 | Anthem Biosciences filed its earnings call presentation on the audited consolidated results for the quarter and year ended March 31, 2026; the earnings call is scheduled for May 20, 2026, at 11:00 AM IST. Q4FY26 revenue from operations was Rs. 6,109 Mn, up 26.4% YoY (CRDMO Rs. 5,128 Mn; Specialty Ingredients Rs.... NSE copy | - | - | -0.9 % |
| 09 Feb 2026 | Anthem Biosciences filed the transcript of its Q3 & 9M FY26 earnings conference call held on February 05, 2026, following its results for the quarter and nine months ended December 31, 2025. Management (CEO Ajay Bhardwaj) reported 9M FY26 consolidated revenue from operations of Rs. 1,513 crore (CRDMO Rs. 1,260... NSE copy | - | - | -0.9 % |
| 12 Nov 2025 | Anthem Biosciences filed the transcript of its Q2 & H1 FY26 earnings conference call held on November 10, 2025, following its unaudited results for the quarter and half year ended September 30, 2025. Management said H1 FY26 consolidated revenue from operations was Rs. 1,090 Cr (CRDMO Rs. 926 Cr, specialty... NSE copy | - | - | +2.8 % |
| 18 Aug 2025 | Anthem Biosciences filed the transcript of its Q1 FY26 earnings conference call held on August 14, 2025, after announcing results for the quarter ended June 30, 2025. Ajay Bhardwaj (MD and CEO) said consolidated revenue from operations was INR540 crores, with CRDMO revenue of INR452.7 crores and speciality... NSE copy | - | - | +1.2 % |
Filings tagged as guidance, newest first (9 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 03 Jul 2026 | Credit rating | Anthem Biosciences Limited filed an intimation under SEBI LODR Regulation 30 that ICRA Limited has revised its credit ratings on the company's bank facilities. ICRA upgraded the Long Term/Short Term fund based working capital (Rs. 175 crore) to [ICRA]AA (Stable) from [ICRA]AA- (Positive), with the short term rating... NSE copy |
| 19 May 2026 | Management change | Anthem Biosciences Limited's board met on May 19, 2026 and approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with an unmodified audit opinion from K. P. Rao & Co. The board recommended a final dividend of INR 2.00 per equity share (face value INR 2.00),... NSE copy |
| 19 May 2026 | Management change | Board of Anthem Biosciences Limited approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with an unmodified audit opinion from K. P. Rao & Co. Board recommended a final dividend of INR 2.00 per equity share (face value INR 2.00) for FY2025-26, subject to... NSE copy |
| 13 Aug 2025 | Management change | Anthem Biosciences Board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, along with the statutory auditors' limited review report (K. P. Rao & Co.), at a meeting held August 13, 2025. The Audit Committee reviewed and recommended the quarterly results to the... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (4 in all). A list of what was filed, not a judgement of the company.